SIIA Público

Obras con ISBN:

No hay obras de este autor.

Documentos en revistas:

1.-		Cardiovascular Safety of VIAN-c4551, an Antiangiogenic Peptide Derived From Vasoinhibin (2025)

2.-		Vasoinhibin is Generated by the Renin-angiotensin System (2025)

3.-		VIAN-c4551 inhibits oxygen-induced retinopathy in mice (2024)

4.-		VIAN-c4551 in eye drops inhibits the excessive retinal vasopermeability induced by VEGF and diabetes in rodents (2024)

5.-		VIAN-c4551 is a potent topical inhibitor of VEGF and Ang-2 that reduces macular edema and angiogenesis in vascular retinopathies (2024)

6.-		VIAN-c4551 delivered in eye drops reaches high therapeutic concentrations in the back of the eye of rabbits (2024)

7.-		Levosulpiride for the treatment of diabetic macular edema: A phase 2, randomized, pilot clinical trial (2023)

8.-		Sulpiride-induced hyperprolactinaemia increases retinal vasoinhibin and protects against diabetic retinopathy in rats (2022)

9.-		Main olfactory bulb reconfiguration by prolonged passive olfactory experience correlates with increased brain-derived neurotrophic factor and improved innate olfaction (2022)

10.-		Global Deletion of the Prolactin Receptor Aggravates Streptozotocin-Induced Diabetes in Mice (2021)

11.-		Levosulpiride Increases the Levels of Prolactin and Antiangiogenic Vasoinhibin in the Vitreous of Patients with Proliferative Diabetic Retinopathy (2020)

Colaboraciones en Tesis:

No hay tesis de este autor.

Patentes:

No hay patentes de este autor.